SCHEMBL607717

SCHEMBL607717

Cc1ccccc1CNC(C)C

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADRA2C P18825 1/20 0.58
KDM4E B2RXH2 2/20 0.53
CHRM2 P08172 1/20 0.50
BCHE P06276 1/20 0.49
ACHE P22303 1/20 0.49
HPGD P15428 3/20 0.46
ALDH1A1 P00352 2/20 0.46
HRH1 P35367 1/20 0.44
KMT2A Q03164 3/20 0.44
TAAR1 Q96RJ0 1/20 0.43
MEN1 O00255 1/20 0.43
HTT P42858 2/20 0.42
GAA P10253 1/20 0.42
LMNA P02545 2/20 0.41
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
ADRB2 P07550 1/20 0.41
ADRB1 P08588 1/20 0.41
ADRB3 P13945 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3272017 0.86 BCHE (0.55) ADRA2CKDM4EBCHEACHEALDH1A1
SCHEMBL25377507 0.83 KDM4E (0.50) ADRA2CKDM4ECHRM2HPGDALDH1A1
SCHEMBL12312588 0.83 BCHE (0.46) ADRA2CKDM4EBCHEACHEALDH1A1
SCHEMBL25377514 0.83 KDM4E (0.50) ADRA2CKDM4ECHRM2HPGDALDH1A1
SCHEMBL25377509 0.83 KDM4E (0.50) ADRA2CKDM4ECHRM2HPGDALDH1A1
SCHEMBL13995685 0.80 KDM4E (0.55) ADRA2CKDM4ECHRM2HPGDALDH1A1
SCHEMBL3679075 0.80 SMN1; SMN2 (0.57) KDM4ECHRM2HPGDALDH1A1KMT2A
SCHEMBL3679074 0.80 SMN1; SMN2 (0.57) KDM4ECHRM2HPGDALDH1A1KMT2A
SCHEMBL13394475 0.80 KDM4E (0.59) ADRA2CKDM4ECHRM2HPGDALDH1A1
SCHEMBL23330373 0.80 HRH1 (0.47) ADRA2CKDM4EBCHEACHEHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120041225-A1 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF VAIDYA NITEEN A (US) 2012-02-16 US claimed
EP-1981831-A2 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF Vaidya, Niteen A. (US) 2008-10-22 EP claimed
WO-2007092264-A2 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF VAIDYA NITEEN A (US) 2007-08-16 WO claimed
US-20070185346-A1 Kit for automated resolving agent selection and method thereof VAIDYA NITEEN A 2007-08-09 US claimed
US-20250136594-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-01 US disclosed
EP-4469438-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
US-20230242565-A1 Macrolides with Modified Desosamine Sugars and Uses Thereof ZIKANI THERAPEUTICS, INC. 2023-08-03 US disclosed
US-11673910-B2 Macrolides with modified desosamine sugars and uses thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2023-06-13 US disclosed
US-20230167104-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-06-01 US disclosed
US-20230159446-A1 Methods and Compositions for Targeting Tregs using CCR8 Inhibitors NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) 2023-05-25 US disclosed
WO-2009042092-A1 2-ARYL OR HETEROARYL INDOLE DERIVATIVES MERCK & CO., INC. (US) 2009-04-02 WO disclosed
US-7504391-B2 Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders SCHERING CORPORATION (US) 2009-03-17 US disclosed
US-20080280925-A1 Amines as Small Molecule Inhibitors METHYLGENE INC. 2008-11-13 US disclosed
US-20070197522-A1 Dpp-iv inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2007-08-23 US disclosed
US-20070185346-A1 Kit for automated resolving agent selection and method thereof VAIDYA NITEEN A 2007-08-09 US disclosed
WO-2006130607-A2 CONTROLLED-RELEASE FORMULATION USEFUL FOR TREATING DISORDERS ASSOCIATED WITH HEPATITIS C VIRUS SCHERING CORPORATION (US) 2006-12-07 WO disclosed
EP-1458729-B1 (ARYL) (AMINO) BORANE COMPOUNDS, METHOD FOR PREPARING SAME CENTRE NAT RECH SCIENT (FR) 2006-03-08 EP disclosed
US-5474994-A Treating hypertension, urethral and lower urinary tract contractions RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) 1995-12-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159446-A1 Methods and Compositions for Targeting Tregs using CCR8 Inhibitors CCR8, CCR1, CCR3 ADRA2C 2033/4885KDM4E 1941/4885CHRM2 4574/4885
US-20250136594-A1 COMPOUNDS AND METHODS OF USE CNKSR1, UGT1A1, REV1 ADRA2C 667/4885KDM4E 1639/4885CHRM2 1738/4885
US-11673910-B2 Macrolides with modified desosamine sugars and uses thereof FUT6, DDOST, MGAM ADRA2C 4438/4885KDM4E 601/4885CHRM2 3268/4885
US-20080280925-A1 Amines as Small Molecule Inhibitors CARM1, PRMT1, PRMT3 ADRA2C 2593/4885KDM4E 369/4885CHRM2 226/4885
US-20120041225-A1 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF ACKR3, KIT, C3AR1 ADRA2C 1162/4885KDM4E 2343/4885CHRM2 2271/4885
US-20070197522-A1 Dpp-iv inhibitors DPP7, DPP4, DPP3 ADRA2C 460/4885KDM4E 1253/4885CHRM2 653/4885
US-20230242565-A1 Macrolides with Modified Desosamine Sugars and Uses Thereof FUT6, DDOST, MGAM ADRA2C 4438/4885KDM4E 601/4885CHRM2 3268/4885
US-20230167104-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 CLK1, CLK2, CLK3 ADRA2C 3303/4885KDM4E 2952/4885CHRM2 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.